 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| 12345678910111213...208209» |
- ||||| AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Enrollment closed, Trial completion date: A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis (clinicaltrials.gov) - Aug 6, 2026
P3, N=208, Active, not recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Jan 2027
- | AiTan (rivoceranib) / Elevar Therapeutics, retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
New P2 trial: SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 6, 2026
P2, N=80, Not yet recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
CAMRELIZUMAB PLUS APATINIB AND EMA/CO IN ULTRA-HIGH-RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA: A PHASE II STUDY (Hall 524) - Aug 6, 2026 - Abstract #IGCS2026IGCS_428;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Efficacy and safety of vunakizumab in the treatment of non-common subtypes of psoriasis: A case report of three Patients (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_5899;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Successful Treatment of Generalized Pustular Psoriasis with Vunakizumab: A Case Series (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_5804;
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Efficacy of Ivarmacitinib for Mild-to-Severe Alopecia Areata: A Case Series (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_5721;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Successful Treatment of Refractory Pyoderma Gangrenosum with Vunakizumab: A Case Report (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_5704;
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Efficacy and Safety of Ivarmacitinib in Adult and Pediatric Patients with Alopecia Areata: A Real-World Analysis (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_5689;
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Real?World Efficacy of Ivarmacitinib for Eyebrow and Eyelash Alopecia in Patients with Alopecia Areata (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_5643;
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
A Case Report: A 14-Year-Old Patient with Severe Alopecia Areata, Vitiligo, and Atopic Dermatitis Undergoing Ivarmacitinib Treatment (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_5392;
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Concomitant Improvement of Severe Alopecia Areata and Vitiligo with the Selective JAK1 Inhibitor Ivarmacitinib: A Case Report (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_5339;
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Efficacy and Safety of Ivarmacitinib in the Treatment of Severe Alopecia Areata: A Retrospective Study (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_5302;
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Ivarmacitinib Response Trajectories in Severe Alopecia Areata: A Post Hoc Analysis of Early, Gradual, Late, and Non?Responder Subgroups Over 52 Weeks (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_5277;
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Rapid Efficacy of Ivarmacitinib in Promoting Scalp Hair, Eyebrow, and Eyelash Regrowth in Alopecia Areata: Chinese Single-Center Real-World Experience in Adults and Minors (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_5271;
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Efficacy of Ivarmacitinib in Severe Alopecia Areata by Prior Treatment History: A Post-Hoc Analysis of a Phase 3 Trial (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_5248;
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Efficacy of Ivarmacitinib in Adults with Severe Alopecia Areata Across Baseline Characteristics: A Post-hoc Analysis of a Phase 3 Trial (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_5162;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Effectiveness and Safety of Vunakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: A Preliminary Analysis of a Real-World Prospective Study (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_5092;
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
JAK inhibitors for the off-label treatment of two stevens-johnson syndrome cases: tofacitinib vs. ivarmacitinib (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_4290;
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Safety Profiles of Ivarmacitinib versus Tofacitinib in Vitiligo Treatment: A Retrospective Comparative Analysis (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_4287;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Real-world efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a prospective cohort study analysing BMI as a predictor of response (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_4194;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Vunakizumab Achieve Complete Remission of Severe Plaque Psoriasis in a 25-Year-Old Male with HIV Infection: A Case Report (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_4147;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Real-world efficacy and safety of vunakizumab in scalp psoriasis: a prospective cohort study (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_4135;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Successful Treatment of A 75-year-old Male with Severe Plaque Psoriasis Using Vunakizumab (antiIL-17)- A Case Report (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_4133;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Successful Treatment of a Patient with Severe Plaque Psoriasis Complicated by Pustular Psoriasis Using Vunakizumab (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_4117;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Rapid Response to Vunakizumab in an Elderly Patient with Generalized Pustular Psoriasis Masquerading as Acute Generalized Exanthematous Pustulosis: A Case Report (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_4113;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Vunakizumab in the Treatment of Severe Erythrodermic Psoriasis with Multiple Organ Dysfunction: A Case Report (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_4107;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Successful Treatment of Severe Generalized Pustular Psoriasis With Concomitant Infection Using Vunakizumab in an 87-Year-Old Patient: A Case Report (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_4093;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Successful treatment of moderate-to-severe hidradenitis suppurativa with Anti-IL-17A Agent Vunakizumab (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_3580;
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
A retrospective observational study of oral ivarmacitinib and narrow-band ultraviolet-B in refractory progressive vitiligo (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_3349;
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Efficacy of Ivarmacitinib in Vitiligo Treatment: A Retrospective Analysis of 7 Cases (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_3326;
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Twenty-four-week clinical outcomes and safety of oral ivarmacitinib in adults with stable non-segmental vitiligo: a real-world retrospective case series (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_3278;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Short-Term Efficacy Observation and Medication Analysis of Vunakizumab in the Treatment of Moderate-to-Severe Plaque Psoriasis (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_3174;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Follicular Psoriasis Successfully Treated with Vunakizumab: A Case Report (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_3154;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
The impact of immunogenicity on the efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a post hoc analysis of a phase 3 trial (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_3116;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Efficacy and Safety of Vunakizumab in the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Report of two Cases. (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_3073;
- SHR-1819 / Jiangsu Hengrui Pharma
Safety, Pharmacokinetics, and Pharmacodynamics of SHR-1819 in Children and Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis:Results from a Multicenter, Open-label, Single-arm Phase Ib/II Study (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_1945;
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis, rocatinlimab (AMG 451) / Kyowa Kirin
OX40/OX40L Clinical Response Lag: A Systematic Review And Pharmacodynamic Analysis Of Amiltelimab, Rocatinlimab, And Ivarmacitinib. Proposing A New "Delayed Onset" Classification System For T-Cell Rebalancing Therapies In Atopic Dermatitis (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_1862;
- AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Efficacy and Safety of Vunakizumab in the Treatment of Moderate-to-Severe Plaque Psoriasis in Patients with High Body Weight (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_1766;
- | AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics, Oncaspar liquid (pegaspargase) / Servier
Trial completion: Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL (clinicaltrials.gov) - Aug 3, 2026
P=N/A, N=61, Completed, Sponsor: Rong Tao
Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Jan 2027 Recruiting --> Completed
- || ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment open: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity (clinicaltrials.gov) - Jul 31, 2026
P1, N=48, Recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Recruiting --> Completed Not yet recruiting --> Recruiting
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Adebrelimab Combined With Famitinib and Chemotherapy as First-Line Treatment for ES-SCLC: A Prospective Case Series () - Jul 31, 2026 - Abstract #IASLCWCLC2026IASLC_WCLC_3067;
Not yet recruiting --> Recruiting Abstract is embargoed at this time.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Neoadjuvant Adebrelimab Plus Chemotherapy Followed by Surgery in Resectable Stage II-III Small Cell Lung Cancer () - Jul 31, 2026 - Abstract #IASLCWCLC2026IASLC_WCLC_3049;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Neoadjuvant Adebrelimab Combined With Chemotherapy Followed by Surgical Resection for Limited-Stage Small-Cell Lung Cancer: A Cohort Study () - Jul 31, 2026 - Abstract #IASLCWCLC2026IASLC_WCLC_3040;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
EP11. Metastatic NSCLC () - Jul 31, 2026 - Abstract #IASLCWCLC2026IASLC_WCLC_2947;
Novel therapeutic strategies are highlighted through anti-IL-6/PD-L1 and PD-1/VEGF-targeting bispecifics, adebrelimab plus ivarmacitinib, avidity-tuned CAR T cells for KRAS-mutant disease, LAG-3 radionuclide therapy, and proteasome inhibitor combinations, alongside real-world data on salvage surgery, ICI use in HBV- and HIV-positive patients, and management of checkpoint inhibitor pneumonitis. Together, these presentations capture the rapidly expanding frontier of NSCLC immunotherapy, integrating translational insights, novel agents, and pragmatic clinical questions to inform the next generation of patient care.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Neoadjuvant Adebrelimab Plus Nab-Paclitaxel and Carboplatin for Unresectable Locally Advanced Thymic Carcinoma: A Single-Arm, Phase II Trial (Exhibits and Posters, Hall C, 3F) - Jul 31, 2026 - Abstract #IASLCWCLC2026IASLC_WCLC_2664;
Together, these presentations capture the rapidly expanding frontier of NSCLC immunotherapy, integrating translational insights, novel agents, and pragmatic clinical questions to inform the next generation of patient care. Abstract is embargoed at this time.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Adebrelimab Plus Famitinib and Chemotherapy for Advanced NSCLC After Progression With PD-1-based Therapy (Exhibits and Posters, Hall C, 3F) - Jul 31, 2026 - Abstract #IASLCWCLC2026IASLC_WCLC_2295;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab Plus Ivarmacitinib With or Without Chemotherapy as First-Line Treatment for Advanced NSCLC: A Phase 2 Trial (Exhibits and Posters, Hall C, 3F) - Jul 31, 2026 - Abstract #IASLCWCLC2026IASLC_WCLC_2280;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- tizetatug rezetecan (SHR-A1921) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Preliminary Efficacy and Safety of TROP2-ADC SHR-A1921 Plus Adebrelimab in Advanced Driver-Negative NSCLC After First-Line Standard Therapy (Exhibits and Posters, Hall C, 3F) - Jul 31, 2026 - Abstract #IASLCWCLC2026IASLC_WCLC_2251;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- Avastin (bevacizumab) / Roche, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab Plus Bevacizumab and Nab-Paclitaxel in Non-Squamous NSCLC After 1st-Line ICI Failure: A Phase II Rechallenge Study (Exhibits and Posters, Hall C, 3F) - Jul 31, 2026 - Abstract #IASLCWCLC2026IASLC_WCLC_1929;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Long-Term Outcomes of Brain Radiotherapy Plus Camrelizumab and Chemotherapy in Untreated NSCLC With Brain Metastases (C-Brain) (Exhibits and Posters, Hall C, 3F) - Jul 31, 2026 - Abstract #IASLCWCLC2026IASLC_WCLC_1923;
Abstract is embargoed at this time. Abstract is embargoed at this time.